Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.

Clinical lymphoma, myeloma & leukemia - 1 Dec 2012

Treon Steven P, Tripsas Christina, Hanzis Christina, Ioakimidis Leukothea, Patterson Christopher J, Manning Robert J, Sheehy Patricia, Turnbull Barry, Hunter Zachary R

Abstract excerpt

UNLABELLED: Familial disease is common in Waldenström macroglobulinemia (WM). We examined the impact of familial disease status on treatment outcome in WM and observed that familial disease was associated with inferior outcomes. However patients with familial WM receiving a bortezomib-containing regimen showed improved treatment outcomes vs. those receiving non–bortezomib-containing regimens....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Boronic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bortezomib

Share to Cyclophosphamide

Share to Disease-Free Survival

Share to Pyrazines

Share to Vidarabine

Share to Waldenstrom Macroglobulinemia

Source

Identifiers

PMID: 23084402
DOI: 10.1016/j.clml.2012.08.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.PMID 23084402Read ↗

Associated malignancies in patients with Waldenström's macroglobulinemia and their kin.Semantic proximity Read ↗

Familial Waldenström Macroglobulinemia: Families Informing Populations.Semantic proximity Read ↗

Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.Semantic proximity Read ↗

Waldenström macroglobulinemia.Semantic proximity Read ↗

Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study.Semantic proximity Read ↗

Clinical application of genomics in Waldenström macroglobulinemia.Semantic proximity Read ↗

The Direction of Modern Therapies in Waldenström Macroglobulinaemia.Semantic proximity Read ↗

Toward personalized treatment in Waldenström macroglobulinemia.Semantic proximity Read ↗

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after the BTK inhibitor era.Semantic proximity Read ↗

Current therapy guidelines for Waldenstrom's macroglobulinaemia.Semantic proximity Read ↗

Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition.Semantic proximity Read ↗

Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.